Uptake of combination antiretroviral therapy and HIV disease progression according to geographical origin in seroconverters in Europe, Canada, and Australia

Inma Jarrin; Nikos Pantazis; M John Gill; Ronald Geskus; Santiago Perez-Hoyos; Laurence Meyer; Maria Prins; Giota Touloumi; Anne Johnson; Osamah Hamouda; Patricia García de Olalla; Kholoud Porter; Julia del Amo; CASCADE Collaboration in EuroCoord; Ole Kirk

doi:10.1093/cid/cir814

Uptake of combination antiretroviral therapy and HIV disease progression according to geographical origin in seroconverters in Europe, Canada, and Australia

Inma Jarrin, Nikos Pantazis, M John Gill, Ronald Geskus, Santiago Perez-Hoyos, Laurence Meyer, Maria Prins, Giota Touloumi, Anne Johnson, Osamah Hamouda, Patricia García de Olalla, Kholoud Porter, Julia del Amo, CASCADE Collaboration in EuroCoord, Ole Kirk

15 Citationer (Scopus)

Abstract

Background. We examined differences by geographical origin (GO) in time from HIV seroconversion (SC) to AIDS, death, and initiation of antiretroviral therapy (cART). Methods. Data from HIV seroconverter cohorts in Europe, Australia and Canada (CASCADE) was used; GO was classified as: western countries (WE), North Africa and Middle East (NAME), sub-Saharan Africa (SSA), Latin America (LA), and Asia (ASIA). Differences by GO were assessed using Cox models. Administrative censoring date was 30 June 2008. Results. Of 16941 seroconverters, 15548 were from WE, 158 NAME, 762 SSA, 349 LA, and 124 ASIA. We found no differences by GO in risks of AIDS (P=.99) and death (P=.12), although seroconverters from NAME (adjusted hazard ratio [aHR]: 0.57; 95% CI: 0.33-.94) and SSA (aHR: 0.74; 95% CI: 0.50-1.10) appeared to have lower mortality than WE. Chances of initiating cART differed by GO (P<.001): seroconverters from SSA were more likely to initiate cART than WE (aHR: 1.48; 95% CI: 1.26-1.74), but not after adjustment for CD4 at SC (aHR: 1.11; 95% CI: 0.88-1.40). Conclusions. In settings with universal access to healthcare, GO does not play a major role in HIV disease progression.

Originalsprog	Engelsk
Tidsskrift	Clinical Infectious Diseases
Vol/bind	54
Udgave nummer	1
Sider (fra-til)	111-8
Antal sider	8
ISSN	1058-4838
DOI	https://doi.org/10.1093/cid/cir814
Status	Udgivet - 1 jan. 2012

FN’s Verdensmål

Dette resultat bidrager til følgende verdensmål

Adgang til dokumentet

10.1093/cid/cir814

Citationsformater

Jarrin, I., Pantazis, N., Gill, M. J., Geskus, R., Perez-Hoyos, S., Meyer, L., Prins, M., Touloumi, G., Johnson, A., Hamouda, O., de Olalla, P. G., Porter, K., del Amo, J., CASCADE Collaboration in EuroCoord, & Kirk, O. (2012). Uptake of combination antiretroviral therapy and HIV disease progression according to geographical origin in seroconverters in Europe, Canada, and Australia. Clinical Infectious Diseases, 54(1), 111-8. https://doi.org/10.1093/cid/cir814

Jarrin, I, Pantazis, N, Gill, MJ, Geskus, R, Perez-Hoyos, S, Meyer, L, Prins, M, Touloumi, G, Johnson, A, Hamouda, O, de Olalla, PG, Porter, K, del Amo, J, CASCADE Collaboration in EuroCoord & Kirk, O 2012, 'Uptake of combination antiretroviral therapy and HIV disease progression according to geographical origin in seroconverters in Europe, Canada, and Australia', Clinical Infectious Diseases, bind 54, nr. 1, s. 111-8. https://doi.org/10.1093/cid/cir814

@article{116678a38e8740c5bd779b11ec3b8f01,

title = "Uptake of combination antiretroviral therapy and HIV disease progression according to geographical origin in seroconverters in Europe, Canada, and Australia",

abstract = "Background. We examined differences by geographical origin (GO) in time from HIV seroconversion (SC) to AIDS, death, and initiation of antiretroviral therapy (cART). Methods. Data from HIV seroconverter cohorts in Europe, Australia and Canada (CASCADE) was used; GO was classified as: western countries (WE), North Africa and Middle East (NAME), sub-Saharan Africa (SSA), Latin America (LA), and Asia (ASIA). Differences by GO were assessed using Cox models. Administrative censoring date was 30 June 2008. Results. Of 16941 seroconverters, 15548 were from WE, 158 NAME, 762 SSA, 349 LA, and 124 ASIA. We found no differences by GO in risks of AIDS (P=.99) and death (P=.12), although seroconverters from NAME (adjusted hazard ratio [aHR]: 0.57; 95% CI: 0.33-.94) and SSA (aHR: 0.74; 95% CI: 0.50-1.10) appeared to have lower mortality than WE. Chances of initiating cART differed by GO (P<.001): seroconverters from SSA were more likely to initiate cART than WE (aHR: 1.48; 95% CI: 1.26-1.74), but not after adjustment for CD4 at SC (aHR: 1.11; 95% CI: 0.88-1.40). Conclusions. In settings with universal access to healthcare, GO does not play a major role in HIV disease progression.",

author = "Inma Jarrin and Nikos Pantazis and Gill, {M John} and Ronald Geskus and Santiago Perez-Hoyos and Laurence Meyer and Maria Prins and Giota Touloumi and Anne Johnson and Osamah Hamouda and {de Olalla}, {Patricia Garc{\'i}a} and Kholoud Porter and {del Amo}, Julia and Ole Kirk and Ole Kirk",

year = "2012",

month = jan,

day = "1",

doi = "10.1093/cid/cir814",

language = "English",

volume = "54",

pages = "111--8",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

number = "1",

}

TY - JOUR

T1 - Uptake of combination antiretroviral therapy and HIV disease progression according to geographical origin in seroconverters in Europe, Canada, and Australia

AU - Jarrin, Inma

AU - Pantazis, Nikos

AU - Gill, M John

AU - Geskus, Ronald

AU - Perez-Hoyos, Santiago

AU - Meyer, Laurence

AU - Prins, Maria

AU - Touloumi, Giota

AU - Johnson, Anne

AU - Hamouda, Osamah

AU - de Olalla, Patricia García

AU - Porter, Kholoud

AU - del Amo, Julia

AU - CASCADE Collaboration in EuroCoord

AU - Kirk, Ole

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Background. We examined differences by geographical origin (GO) in time from HIV seroconversion (SC) to AIDS, death, and initiation of antiretroviral therapy (cART). Methods. Data from HIV seroconverter cohorts in Europe, Australia and Canada (CASCADE) was used; GO was classified as: western countries (WE), North Africa and Middle East (NAME), sub-Saharan Africa (SSA), Latin America (LA), and Asia (ASIA). Differences by GO were assessed using Cox models. Administrative censoring date was 30 June 2008. Results. Of 16941 seroconverters, 15548 were from WE, 158 NAME, 762 SSA, 349 LA, and 124 ASIA. We found no differences by GO in risks of AIDS (P=.99) and death (P=.12), although seroconverters from NAME (adjusted hazard ratio [aHR]: 0.57; 95% CI: 0.33-.94) and SSA (aHR: 0.74; 95% CI: 0.50-1.10) appeared to have lower mortality than WE. Chances of initiating cART differed by GO (P<.001): seroconverters from SSA were more likely to initiate cART than WE (aHR: 1.48; 95% CI: 1.26-1.74), but not after adjustment for CD4 at SC (aHR: 1.11; 95% CI: 0.88-1.40). Conclusions. In settings with universal access to healthcare, GO does not play a major role in HIV disease progression.

AB - Background. We examined differences by geographical origin (GO) in time from HIV seroconversion (SC) to AIDS, death, and initiation of antiretroviral therapy (cART). Methods. Data from HIV seroconverter cohorts in Europe, Australia and Canada (CASCADE) was used; GO was classified as: western countries (WE), North Africa and Middle East (NAME), sub-Saharan Africa (SSA), Latin America (LA), and Asia (ASIA). Differences by GO were assessed using Cox models. Administrative censoring date was 30 June 2008. Results. Of 16941 seroconverters, 15548 were from WE, 158 NAME, 762 SSA, 349 LA, and 124 ASIA. We found no differences by GO in risks of AIDS (P=.99) and death (P=.12), although seroconverters from NAME (adjusted hazard ratio [aHR]: 0.57; 95% CI: 0.33-.94) and SSA (aHR: 0.74; 95% CI: 0.50-1.10) appeared to have lower mortality than WE. Chances of initiating cART differed by GO (P<.001): seroconverters from SSA were more likely to initiate cART than WE (aHR: 1.48; 95% CI: 1.26-1.74), but not after adjustment for CD4 at SC (aHR: 1.11; 95% CI: 0.88-1.40). Conclusions. In settings with universal access to healthcare, GO does not play a major role in HIV disease progression.

U2 - 10.1093/cid/cir814

DO - 10.1093/cid/cir814

M3 - Journal article

C2 - 22109944

SN - 1058-4838

VL - 54

SP - 111

EP - 118

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

IS - 1

ER -

Uptake of combination antiretroviral therapy and HIV disease progression according to geographical origin in seroconverters in Europe, Canada, and Australia

Abstract

FN’s Verdensmål

Adgang til dokumentet

Fingeraftryk

Citationsformater